Stocktoria
Immunocore Holdings plc IMCR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-05
Chart by TradingView
3/9
Piotroski F — financial health
2.37
Altman Z″ — distress risk · grey
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Revenue | $400.0M | $310.2M | $249.4M | $174.4M |
| Operating income | -$45.4M | -$70.5M | -$59.6M | -$51.7M |
| Net income | -$35.5M | -$51.1M | -$55.3M | -$52.5M |
| Operating cash flow | -$10.7M | $26.1M | $2.9M | -$49.2M |
| Free cash flow | -$15.1M | $20.9M | -$2.5M | -$51.4M |
| Total assets | $1.1B | $1.0B | $597.0M | $526.8M |
| Total liabilities | $686.2M | $648.8M | $228.2M | $187.9M |
| Shareholders' equity | $381.0M | $360.7M | $368.8M | $338.9M |
| Ratios | ||||
| Operating margin | -11.3% | -22.7% | -23.9% | -29.7% |
| Net margin | -8.9% | -16.5% | -22.2% | -30.1% |
| FCF margin | -3.8% | 6.7% | -1.0% | -29.5% |
| Return on assets | -3.3% | -5.1% | -9.3% | -10.0% |
| Return on equity | -9.3% | -14.2% | -15.0% | -15.5% |
| Current ratio | 4.04 | 4.38 | 3.80 | 4.70 |
| Revenue growth | 29.0% | 24.4% | 43.1% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 1,102,271 | $33.2M |
| RENAISSANCE TECHNOLOGIES LLC | 164,000 | $4.9M |
| Bridgewater Associates, LP | 18,930 | $570,740 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.37 (grey)
- Working capital / assets 0.703
- Retained earnings / assets -0.779
- EBIT / assets -0.042
- Equity / liabilities 0.555
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001671927 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.